摘要
呼吸道合胞病毒感染是引起婴儿、儿童、免疫力低下的病人、老年人等高危人群患病和死亡的一个重要因素,在这样高疾病风险下,还没有一种安全有效的疫苗上市。因此,呼吸道合胞病毒疫苗已被WHO列为全球最优先发展的疫苗之一。该文对呼吸道合胞病毒的结构、感染机制、病毒的F和G两种重要蛋白等生物学性状、主动和被动免疫疫苗的发展以及存在的一些问题等方面进行综述。
Respiratory syncytial virus(RSV) infection is an important factor for causing illness and death in global high-risk groups, such as infants, children, and immunocompromised patients, and the elderly. As a high risk factor, there is still no safe and effective vaccine. Therefore, RSV vaccine has been regarded as one of the vaccines that needs to be developed globally by the World Health Organization(WHO). The important biological characteristics such as the structure of RSV,infection mechanism, and two important glycoproteins: fusion and attachment, active and passive immunization vaccine development, as well as some of the aspects were reviewed.
作者
杨宇婷
赵耀
Yang Yuting;Zhao Yao(Center for Child Infection and Immu- nological Disorders, Pediatric Research Institute, Ministry of Education Key Laboratory of Child Development and Disorders, Children's Hospital of Chongqing Medical University, Chongqing 400014, China)
出处
《国际儿科学杂志》
2018年第4期267-270,共4页
International Journal of Pediatrics
关键词
呼吸道合胞病毒
疫苗
免疫原性
安全性
Respiratory syncyfial virus
Vaccine
Immunogenicity
Security